SCHEMBL25933740

SCHEMBL25933740

Cc1ccc(Oc2ccc(-c3nn(C4CCN(C5CCN(C(=O)OC(C)(C)C)CC5)CC4)c4ncnc(N)c34)cc2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BTK Q06187 16/20 0.60
EGFR P00533 3/20 0.60
LCK P06239 4/20 0.59
SRC P12931 4/20 0.59
KDR P35968 2/20 0.59
TEK Q02763 1/20 0.59
NUDT14 O95848 1/20 0.58
NUDT5 Q9UKK9 1/20 0.58
ITK Q08881 1/20 0.57
PIK3CD O00329 1/20 0.54
ABL1 P00519 1/20 0.54
HCK P08631 1/20 0.54
PIK3CA P42336 1/20 0.54
PIK3CB P42338 1/20 0.54
MTOR P42345 1/20 0.54
PIK3CG P48736 1/20 0.54
EPHB4 P54760 1/20 0.54
PRKDC P78527 1/20 0.54
PI4KB Q9UBF8 1/20 0.54
LYN P07948 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25933738 0.97 BTK (0.63) BTKEGFRLCKSRCKDR
SCHEMBL25933742 0.95 BTK (0.59) BTKEGFRLCKSRCKDR
SCHEMBL5801559 0.94 BTK (0.69) BTKEGFRLCKSRCKDR
SCHEMBL22720717 0.94 BTK (0.69) BTKEGFRLCKSRCKDR
SCHEMBL22720690 0.94 BTK (0.69) BTKEGFRLCKSRCKDR
SCHEMBL24196859 0.94 BTK (0.60) BTKEGFRLCKSRCKDR
SCHEMBL22720698 0.94 BTK (0.69) BTKEGFRLCKSRCKDR
SCHEMBL30416568 0.94 BTK (0.60) BTKEGFRLCKSRCKDR
SCHEMBL29470248 0.94 BTK (0.69) BTKEGFRLCKSRCKDR
SCHEMBL25933728 0.93 BTK (0.59) BTKEGFRLCKSRCKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230248833-A1 COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) 2023-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230248833-A1 COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR BTK, WEE1, WEE2 BTK 1/4885EGFR 2234/4885LCK 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.